Oswaldo Julio Ramirez

Mrs. Oswaldo Julio Ramirez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Subham Kumar VishwakarmaSubham Kumar Vishwakarma
Subham Kumar Vishwakarma
Oswaldo Julio RamirezOswaldo Julio Ramirez
Oswaldo Julio Ramirez
Heitor Leocádio de Souza RodriguesHeitor Leocádio de Souza Rodrigues
Heitor Leocádio de Souza Rodrigues
LPLaura Maria Duran Gleriani Primo
Laura Maria Duran Gleriani Primo
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), remains one of the most devastating infectious diseases worldwide, with rising multidrug resistance limiting the effectiveness of conventional treatments. Novel therapeutic approaches are urgently needed to complement or replace existing regimens. Among emerging candidates, antimicrobial peptides (AMPs) stand out as versatile molecules capable of exerting direct antimycobacterial effects while also modulating the host immune response. This review explores peptide-based strategies against TB, with a focus on four major axes of innovation. First, we examine host-directed pathways, including the vitamin D–cathelicidin axis and other immunomodulatory mechanisms and their regulatory role in the induction of endogenous AMPs such as cathelicidin LL-37, which contributes to host-directed defense. Second, we discuss peptide-based vaccines designed to elicit robust and durable protective immunity, representing a complementary alternative to classical vaccine approaches. Third, we highlight the synergistic potential of AMPs in combination with first-line and second-line anti-TB drugs, aiming to restore or enhance bactericidal activity against resistant strains. Finally, we analyze technological platforms, including nanocarriers and inhalable formulations, that enable targeted pulmonary delivery, improve peptide stability, and enhance bioavailability. By integrating molecular design, immune modulation, and advanced delivery systems, peptide-based strategies provide a multifaceted approach to overcoming the limitations of current TB therapy. Collectively, these advances position AMPs not only as promising standalone agents but also as key components in combination and host-directed therapies, with strong potential to reshape the future clinical management of tuberculosis.

14 October 2025 in ACS Measurement Science Au
Verified
Journal Article
Open access
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Oswaldo Julio RamirezOswaldo Julio Ramirez
Oswaldo Julio Ramirez
LPLaura Maria Duran Gleriani Primo
Laura Maria Duran Gleriani Primo
EDEmma Dyhr
Emma Dyhr
ISIngvill Pedersen Sæbø
Ingvill Pedersen Sæbø
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
The global burden of multidrug-resistant tuberculosis (MDR-TB) underscores the urgent need for novel therapeutics with distinct mechanisms of action. Here, we report a comparative evaluation of four antimicrobial peptides (AMPs) derived from the amphibian peptide B1CTcu5, integrating experimental validation with molecular modeling to elucidate structure–activity relationships. Among them, W-B1CTcu5, featuring a single N-terminal tryptophan substitution, exhibited the most potent antimycobacterial activity (MIC = 3.2 μg/mL) against Mycobacterium tuberculosis (MTB) combined with high structural stability, persistent membrane interaction, and multitarget affinity against key MTB proteins, including the porin MspA, the transporter CpnT, and the cell wall enzyme Ag85B. In contrast, analogs with reduced hydrophobic anchoring or dynamic instability demonstrated diminished efficacy despite partial membrane insertion or surface affinity. Molecular dynamics simulations revealed that peptides with low root-mean-square deviation and minimal residue fluctuation retained compact, α-helical conformations and maintained productive bilayer engagement, which are traits correlated with antimicrobial performance. However, the hemolytic properties of W-B1CTcu5 highlight a therapeutic trade-off between potency and host toxicity. Together, these findings emphasize the predictive power of dynamic structural descriptors in AMP design, and identify W-B1CTcu5 as a promising, yet optimization-requiring, scaffold for future design of anti-TB AMPs.

24 March 2026 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
Subham Kumar VishwakarmaSubham Kumar Vishwakarma
Subham Kumar Vishwakarma
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Oswaldo Julio RamirezOswaldo Julio Ramirez
Oswaldo Julio Ramirez
AMAditya Mishra
Aditya Mishra
ZQZidane QRIOUET
Zidane QRIOUET
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
Structure-based strategies are widely used in tuberculosis drug discovery; however, their translational impact remains limited. This review examines how structure-based virtual screening (SBVS) is applied in practice to Mycobacterium tuberculosis targets and explores why docking-derived predictions frequently fail to translate into measurable biological activity. Rather than treating docking scores as quantitative predictors of potency, representative case studies are analyzed to demonstrate that SBVS is most effective when employed as a prioritization framework integrated with appropriate target preparation, physicochemical filtering, and early experimental validation. Across diverse targets, molecular dynamics simulations emerge as a critical discriminator, enabling the identification of binding instability and false-positive hits that persist after static docking. Tuberculosis-specific constraints—including cofactor-dependent catalysis, resistance-associated mutations, membrane-rich environments, and permeability barriers—are discussed as key factors decoupling in silico affinity from whole-cell efficacy. Collectively, these observations support a workflow-oriented view of computational drug discovery in tuberculosis, in which iterative integration of structural modeling and experimental validation is required for meaningful lead identification.